Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Fosun Pharma, officially known as Shanghai Fosun Pharmaceutical (Group) Co., Ltd., is a prominent player in the global healthcare sector, headquartered in Shanghai, China. Established in 1994, the company has made significant strides in the pharmaceutical and healthcare industries, focusing on research and development, manufacturing, and distribution of a diverse range of medical products and services.
Operating primarily in China and expanding its reach internationally, Fosun Pharma is recognised for its innovative approach to drug development and healthcare solutions. The company offers a unique portfolio that includes prescription drugs, vaccines, and diagnostic products, setting itself apart through strategic partnerships and a commitment to quality. With a strong market position, Fosun Pharma has achieved notable milestones, including successful collaborations and acquisitions that enhance its global footprint in the healthcare landscape.
+8 vs industry average
Fosun Pharma’s score of 44 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Business Services is among the most carbon-intensive industries
The Business Services industry has reduced its overall emissions by 25% since 2018
Scope 3 accounts for ••• of total emissions.
Fosun Pharma reported total emissions of approximately 929.4 million kg CO2e in 2024. This includes about 184.0 million kg CO2e from Scope 1, 653.6 million kg CO2e from Scope 2, and 91.8 million kg CO2e from Scope 3.
The company has set several climate commitments. Fosun Pharma aims to reduce its carbon emission intensity (Scope 2) by 15% by 2025 compared to 2020 levels, targeting 0.23 tonnes per RMB 10,000 revenue. Additionally, they plan to reduce comprehensive energy consumption intensity (Scope 1) by 10% by 2025 compared to 2020 levels, aiming for 2.287 GJ per RMB 10,000 revenue. Fosun Pharma also acknowledges the International Energy Agency's proposed plan to achieve net-zero emissions by 2050.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more